NovaBay Pharmaceuticals, Inc. (formerly known as NovaCal Pharmaceuticals, Inc.) to Present Human Clinical Data on Lead Anti-Infective Compound at the 48th Annual IDSA Meeting

EMERYVILLE, Calif., Oct. 15, 2010 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announces that it will deliver two poster presentations on its compounds at the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA). The conference will take place October 21-24, 2010, at the Vancouver Convention and Exhibition Centre in Vancouver, British Columbia, Canada.

MORE ON THIS TOPIC